Tempus AI (TEM) announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. The event will take place May 30 – June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company’s use of AI-driven solutions to advance precision oncology. “At ASCO 2025, we are proud to showcase a diverse portfolio of studies that highlight how our cutting-edge technologies, including tumor-naive and tumor-informed MRD monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling, are providing clinicians and researchers with actionable insights to personalize treatment and improve outcomes for patients,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “We are excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI Stock (TEM) Could See ‘Tesla or Nvidia-Type Inflection,’ Claims Short Seller
- Cathie Wood’s ARK Investment bought 251K shares of Tempus AI today
- AI Daily: Nvidia suppliers accelerate production of Blackwell AI server racks
- Tempus AI down 3% after Spruce Point short report
- Spruce Point short Tempus AI, sees 50%-60% potential downside risk
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue